GSK's Ris-Rez Shows 61% Response Rate in Small Cell Lung Cancer Trial

3-line summary

• GSK said Monday its experimental lung-cancer drug risvutatug rezetecan (Ris-Rez), licensed from China's Hansoh Pharma, showed a confirmed response in 11 of 18 evaluable patients (about 61%) at the high 8 mg/kg dose in an early global trial of extensive-stage small cell lung cancer patients who had relapsed after prior treatment, versus 7 of 22 (32%) at the lower 6 mg/kg dose; Grade 3-or-higher adverse events were more frequent at the high dose (42%) than the low dose (15%).
• The trial enrolled 50 patients, most previously treated with two prior therapies, with roughly 100.5 days of follow-up and enrollment still ongoing; standard-of-care median overall survival for this setting is about 12-13 months, though the article did not give a direct standard-of-care response-rate comparison. GSK said longer follow-up is needed to assess durability of response, and results will be presented at the ESMO Congress 2026 in Madrid.
• GSK will advance the 8 mg/kg dose into its global late-stage trial EMBOLD SCLC-301, a decision informed by this data and by Hansoh's pivotal China trial, which GSK said showed a statistically significant overall-survival improvement; GSK holds exclusive global rights to the drug excluding mainland China, Hong Kong, Macau, and Taiwan, and more than 1,000 patients have received it across trials including a late-stage study in hormone-resistant prostate cancer.

This summary is our own processing of the source article; see the source link below for full context.